These findings indicate that disrupting the NAT10/DKK2 axis synergizes with PD-1 blockade to reinvigorate CD8+ T cell–mediated antitumor immunity, proposing a potential combinatorial immunotherapy strategy for CRC. The gene discussed is NAT10; the disease is colorectal carcinoma.